Calanolide A. Antiviral for AIDS, reverse transcriptase inhibitor

Drugs of the Future

Volumn 24, Issue 3, 1999, Pages 235-245

  Sorbera, L A ^a   Leeson, P ^a   Castaner J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CALANOLIDE A; DELAVIRDINE; EFAVIRENZ; EMIVIRINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TALVIRALINE; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL TRIAL; DRUG ACTIVITY; DRUG EFFECT; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; REVIEW;

EID: 0032958374     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1999.024.03.474035     Document Type: Review

References (87)

1. Boyd, M.R., Cardellina, J.H. II, Gustafson, K.R., McMahon, J.B., Fuller, R.W., Cragg, G.M., Kashman, Y (Dept. Health & Human Services; Univ. Illinois). Calanolide antiviral cpds., compsns. and uses thereof. EP 633887, JP 96502948, JP 96507311, WO 9320082, WO 9428000, US 5591770.
2. Kashman, Y, Gustafson, K.R., Fuller, R.W., Cardellina, J.H. II, McMahon, J.B., Currens, M.J., Buckheit, R.W. Jr., Hughes, S.H., Cragg, G.M., Boyd, M.R. The calanolides, a novel HIV-inhibitory class of coumarin derivatives from the tropical rain forest tree, Calophyllum lanigerum. J Med Chem 1992, 35: 2735-43.
3. Kucherenko, A., Ravin, M.T., Boulanger, W.A., Khilevich, A., Shone, R.L., Rizzo, J.D., Sheinkman, A.K., Xu, Z.-Q. Novel approach for synthesis of (±)-calanolide A and its anti-HIV activity. Tetrahedron Lett 1995, 36: 5475-8.
4. Flavin, M.T., Rizzo, J.D., Khilevich, A. et al. Synthesis, Chromatographic resolution, and anti-human immunodeficiency virus activity of (±)-calanolide A and its enantiomers. J Med Chem 1996, 39: 1303-13.
5. Flavin, M.T., Xu, Z.-Q., Khilevich, A. et al. (MediChem Res., Inc.). Method for the preparation of (+)-calanolide A and analogues thereof. WO 9838193.
6. Cardellina, J.H. II, Bokesch, H.R., McKee, T.C., Boyd, M.R. Resolution and comparative anti-HIV evaluation of the enantiomers of calanolides A and B. Bioorg Med Chem Lett 1995, 5: 1011-4.
7. Deshpande, P.P., Tagliaferri, F., Victory, S.F., Yan, S., Baker, D.C. Synthesis of optically active calanolides A and B. J Org Chem 1995, 60: 2964-5.
8. Baker, D.C., Deshpande, P.P., Yan, S., Tagliaferri, F., Victory, S.F. (Univ. Tennessee Res. Corp.). Synthesis of optically active calanolides A and B and enantiomers and related cpds. WO 9626934.
9. Trost, B.M., Toste, F.D. A catalytic enantioselective approach to chromans and chromanols. A total synthesis of (-)-calanolides A and B and the vitamin E nucleus. J Am Chem Soc 1998,120: 9074-5.
10. Khilevich, A., Mar, A., Flavin, M.T. et al. Synthesis of (+)-calanolide A, an anti-HIV agent, via enzyme-catalyzed resolution of the aldol products. Tetrahedron Asymmetry 1996, 7: 3315-26.
11. 14C-labeled (+)-calanolide A, a naturally occurring anti-HIV agent. J Label Compd Radiopharm 1997, 39: 901-6.
12. Gallo, R.C., Montagnier, L. AIDS in 1988. Sci Am 1988, 259: 41-8.
13. De Clercq, E. Antiviral therapy for human immunodeficiency virus infections. Clin Microbiol Rev 1995, 8: 200-39.
14. De Clercq, E. In search of a selective antiviral chemotherapy. Clin Microbiol Rev 1997, 10: 674-93.
15. Larder, B.A., Darby, G., Richmann, D.D. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989, 243: 1731-4.
16. Lambert, J.S., Seidlin, M., Reichman, R.C., Plank, C.S., Laverty, M., Morse, G.D., Knupp, C., McLaran, C., Pettinelli, C., Valnetin, F.T., Dolin, R. 2',3'-Dideoxyinosine (ddl) in patients with the acquired immunodeficiency syndrome or AIDS related complex. A phase I trial. New Engl J Med 1990, 322: 1333-40.
17. Cooley, T.P., Kunches, L.M., Saunders, C.A., Ritter, J.K., Perkins, C.J., McLaren, C., McCaffrey, R.P., Liebman, H.A. Once-daily administration of2',3'-dideoxyinosine (ddl) in patients with the acquired immunodeficiency syndrome or AIDS related complex. Results of a phase I trial. New Engl J Med 1990, 322: 1340-5.
18. Richman, D.D. HIV drug resistance. AIDS Res Hum Retroviruses 1992, 8: 1065-71.
19. Larder, B.A. Interaction between drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase. J Gen Virol 1994, 75: 951-7.
20. Mayers, D.L., Japour, AJ., Arduino, J.M. et al. The RV43 study group. Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy. Antimicrob Agents Chemother 1994, 38: 307-14.
21. Erice, A., Mayers, D.L., Strike, D.G., Sannerud, K.J., McCutchan, F.E., Henry, K., Balfour, H.H. Jr. Brief report: Primary infection with zidovudine-resistant human immunodeficiency virus type 1. New Engl J Med 1993, 328: 1163-5.
22. Vaishnav, Y.N., Wong-Staal, F. The biochemistry of AIDS. Annu Rev Biochem 1991, 60: 577-630.
23. Goff, S.P. Retroviral reverse transcriptase: Synthesis, structure, and function. J AIDS 1990, 3: 817-31.
24. Jacobo-Molina, A., Arnold, E. HIV reverse transcriptase structure-function relationships. Biochemistry 1991, 30: 6351-61.
25. De Clercq, E. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the treatment of human immunodeficiency virus type 1 (HIV-1) infections: Strategies to overcome drug resistance development. Med Res Rev 1996, 16: 125-57.
26. De Clercq, E. What can be expected from non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the treatment of human immunodeficiency virus type 1 (HIV-1) infections? Rev Med Virol 1996, 6: 97-117.
27. De Clercq, E. The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Antiviral Res 1998, 38: 153-79.
28. Romero, D.L. Advances in the development of HIV reverse transcriptase inhibitors. In: Annual Reports in Medicinal Chemistry, J.A. Bristol (Ed.), Academic Press, New York, 1994, 29: 123-32.
29. Smerdon, S.J., Jager, J., Wang, J., Kohlstaedt, L.A., Chirino, A.J., Friedman, J.M., Rice, P.A., Steitz, T.A. Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1994, 91: 3911-5.
30. Ren, J., Esnouf, R., Garman, E., Somers, D., Ross, C., Kirby, I., Keeling, J., Darby, G., Jones, Y., Stuart, D., Stammers, D. High resolution structures of HIV-1 RT from four RT-inhibitor complexes. Struct Biol 1995, 2: 293-302.
31. Ren, J., Esnouf, R., Hopkins, A., Ross, C., Jones, Y., Stammers, D., Stuart, D. The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: Lessons for inhibitor design. Structure 1995, 3: 915-26.
32. Ding, J., Das, K., Tantillo, C. et al. Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor α-APA R 95845 at 2.8 Å resolution. Structure 1995, 3: 365-79.
33. Esnouf, R., Ren, J., Ross, C., Jones, Y., Stammers, D., Stuart, D. Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. Struct Biol 1995, 2: 303-8.
34. Patil, A.D., Freyer, A.J., Eggleston, D. et al. The nonphyllums, novel inhibitors of HIV-1 reverse transcriptase isolated from the Malaysian tree, Calophyllum inophyllum. J Med Chem 1993, 36: 4131-8.
35. Fuller, R.W., Bokesch, H.R., Gustafsson, K.R., McKee, T.C., Cardellina, J.H. II, McMahon, J.B., Cragg, G.M., Soejarto, D.D., Boyd, M.R. HIV-inhibitory coumarins from latex of the tropical rainforest tree Calophyllum teysmannii var. inophylloide. Bioorg Med Chem Lett 1994, 4: 1961-4.
36. Galinis, D.L., Fuller, R.W., McKee, T.C., Cardellina, J.H. II, Gulakowski, R.J., McMahon, J.B., Boyd, M.R. Structure-activity modifications of the HIV-1 inhibitors (+)-calanolide A and (-)-calanolide B. J Med Chem 1996, 39: 4507-10.
37. Boyer, P.L., Currens, M.J., McMahon, J.B., Boyd, M.R., Hughes, S.H. Analysis of nonnucleoside drug-resistant variants of human immunodeficiency virus type 1 reverse transcriptase. J Virol 1993, 67: 2412-20.
38. Hizi, A., Tal, R., Shaharabany, M., Currens, M.J., Boyd, M.R., Hughes, S.H., McMahon, J.B. Specific inhibition of the reverse transcriptase of human immunodeficiency virus type 1 and the chimeric enzymes of human immunodeficiency virus type 1 and type 2 by nonnucleoside inhibitors. Antimicrob Agents Chemother 1993, 37: 1037-42.
39. Buckheit, R.W. Jr., Fliakas-Boltz, V., Decker, W.D. et al. Comparative anti-HIV evaluation of diverse HIV-1-specific reverse transcriptase inhibitor-resistant virus isolates demonstrates the existence of distinct phenotypic subgroups. Antivir Res 1995, 26: 117-32.
40. Currens, M.J., Gulakowski, R.J., Mariner, J.M., Moran, R.A., Buckheit, R.W. Jr., Gustafson, K.R., McMahon, J.B., Boyd, M.R. Antiviral activity and mechanism of action of calanolide A against the human immunodeficiency virus type-1. J Pharmacol Exp Ther 1996, 279: 645-51.
41. Currens, M.J., Mariner, J.M., McMahon, J.B., Boyd, M.R. Kinetic analysis of inhibition of human immunodeficiency virus type-1 reverse transcriptase by calanolide A. J Pharmacol Exp Ther 1996, 279: 652-61.
42. Buckheit, R., Russell, J., Boltz, V.F., Pallansch, L.A., Xu, Z.Q., Flavin, M. Combination anti-HIV interactions and resistance profile of the nonnucleoside RT inhibitor (+)-calanoide A. 12th World AIDS Conf (June 28-July 3, Geneva) 1998 Abst 12366.
43. Xu, Z.-Q., Hollingshead, M.G., Borgel, S., Elder, C., Khilevich, A., Flavin, M.T. In vivo anti-HIV activity of (+)-calanolide A in the hollow fiber mouse model. Bioorg Med Chem Lett 1999, 9: 133-8.
44. Newman, R.A., Chen, W., Madden, T.L. Pharmaceutical properties of related calanolide compounds with activity against human immunodeficiency virus. J Pharm Sci 1998, 87: 1077-80.
45. Frank, P., Flavin, M.T., Roca-Acin, J., Xu, Z.-Q. Safety assessment of (+)-calanolide A, a naturally occurring anti-HIV agent. 4th Conf Retroviruses Opportunistic Infect (Jan 22-26, Washington DC) 1997, Abst.
46. Ruckle, J., Giltner, J., Creagh, T., Dutta, B., Tolbert, D., Xu, Z.-Q. Clinical safety and pharmacokinetics of (+)-calanolide A, a naturally occurring NNRTI, in normal healthy and HIV-infected volunteers. 6th Conf Retroviruses Opportunistic Infect (Jan 31-Feb 4, Chicago) 1999, Abst 606.
47. Xu, Z.-Q., Creagh, T., Giltner, J., Ruckle, J., Frank, P., Tolbert, D., Flavin, M.T. Preliminary clinical safety and pharmacokinetics profile of (+)-calanolide A, a naturally occurring NNRTI. 12th World AIDS Conf (June 28-July 3, Geneva) 1998, Abst 12216.
48. Lemont firm in search of medical miracle. HIV research: MediChem arming doctors in war against AIDS. Sarawak MediChem Pharmaceuticals, Inc. Web Site Feb 23, 1999.
49. Sarawak MediChem's calanolide compounds featured at ROI conference. Prous Science Daily Essentials Feb 11, 1999.
50. Dueweke, T.J., Poppe, S.M., Romero, D.L. et al. U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication. Antimicrob Agents Chemother 1993, 37: 1127-31.
51. Wishka, D.G., Graber, D.R., Kopta, L.A. et al. (-)-6-Chloro-2-[(1furo[2,3c]pyridin-5-ylethyl)thio]-4-pyrimidinamine, PNU-142721, a new broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitor. J Med Chem 1998, 41: 1357-60.
52. Young, S.D. et al. L-743,726 (DMP-266): A novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. 11th Int Conf AIDS (July 7-12, Vancouver) 1996, Abst Mo.A.1077.
53. Young, S.D., Britcher, S.F., Tran, L.O. L-743,726 (DMP-266): A novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 1995, 39: 2602-5.
54. Yuasa, S., Sadakata, Y., Takashima, H., Sekiya, K., Inouye, N., Ubasawa, M., Baba, M. Selective and synergistic inhibition of human immunodeficiency virus type 1 reverse transcriptase by a non-nucleoside inhibitor, MKC-442. Mol Pharmacol 1993 44: 895-900.
55. Silvestri, R., Artico, M., Bruno, B., Massa, S., Novellino, E., Greco, G., Marongiu, M.E., Pani, A., De Montis, A., La Colla, P. Synthesis and biological evaluation of 5H-indolo[3,2-b][1,5]benzothiazepine derivatives, designed as conformationally constrained analogues of the human immunodeficiency virus type 1 reverse transcriptase inhibitor L-737,126. Antivir Chem Chemother 1998, 9: 139-48.
56. Hargrave, K.D., Proudfoot, J.R., Grozinger, K.G. et al. Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase. 1. Tricyclic pyridobenzo- and dipyridodiazepinones. J Med Chem 1991, 34: 2231-41.
57. Kleim, J.P., Bender, R., Kirsch, R. et al. Preclinical evaluation of HBY 097, a new nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 replication. Antimicrob Agents Chemother 1995, 39: 2253-7.
58. Buckheit, R.W. et al. A diarylsulphone non-nucleoside reverse transcriptase inhibitor with a unique sensitivity profile to drug-resistant virus isolates. Antivir Chem Chemother 1996, 7: 243.
59. Flavin, M.T. et al. In vitro anti-human immunodeficiency virus (HIV) activity of (+)-calanolide A. 4th Conf Retroviruses Opportunistic Infect (Jan 22-26, Washington DC) 1997, Abst.
60. Chong, K.-T., Pagano, P.J. Inhibition of human immunodeficiency virus type 1 infection in vitro by combination of delavirdine, zidovudine and didanosine. Antivir Res 1997, 34: 51-63.
61. Okamoto, M., Makino, M., Yamada, K., Nakade, K., Yuasa, S., Baba, M. Complete inhibition of viral breakthrough by combination ofMKC-442 with AZT during a long-term culture of HIV-1 infected cells. Antivir Res 1996, 31: 69-77.
62. Tanaka, H., Takashima, H., Ubasawa, M., Sekiya, K., Inouye, N., Baba, M., Shigeta, S., Walker, R.T., De Clercq, E., Miyasaka, T. Synthesis and antiviral activity of 6-benzyl analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) as potent and selective anti-HIV-1 agents. J Med Chem 1995, 38: 2860-5.
63. Balzarini, J., Pelemans, H., Aquaro, S., Perno, C.F., Witvrouw, M., Schols, D., De Clercq, E., Karlsson, A. Highly favorable antiviral activity and resistance profile of the novel thiocarboxanilide pentenyloxy ether derivatives UC-781 and UC-82 as inhibitors of human immunodeficiency virus type 1 replication. Mol Pharmacol 1996, 50: 394-401.
64. Furman, P., Barry, D.W., Borroto-Esoda, K., Moxham, C., Richman, D., Sommadossi, J.-P., Endoh, R., Niwa, T., Yamamoto, M., Szczech, G. Preclinical development of MKC-442, a potent and selective non-nucleoside inhibitor of HIV reverse transcriptase. 4th Conf Retroviruses Opportunistic Infect (Jan 22-26, Washington DC) 1997, Abst.
65. Ijichi, K., Fujiwara, M., Nagano, H. et al. Anti-HIV-1 activity of thiadiazole derivatives: Structure-activity relationship, reverse transcriptase inhibition, and lipophilicity. Antivir Res 1996, 31: 87-94.
66. Witvrouw, M., Arranz, M.E., Pannecouque, C. et al. 1,1,3-Trioxo-2H,4H-thieno[3,4-e][1,2,4]thiadiazine (TTD) derivatives: A new class of nonnucleoside human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitors with anti-HIV-1 activity. Antimicrob Agents Chemother 1998, 42: 618-23.
67. Taylor, D.L. et al. Anti-HIV activity of MDL 74968, a novel acyclonucleotide derivative of guanine: Drug resistance and drug combination effects in vitro. Antivir Chem Chemother 1996, 7: 253.
68. Alvarez, R., Velazquez, S., San-Felix, A., Aquaro, S., De Clercq, E., Perno, C.F., Karlsson, A., Balzarini, J., Camarasa, M.J. l,2,3-Triazole-[2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3'- spiro-5″-(4″-amino-1″,2″-oxathiole 2″,2″-dioxide) (TSAO) analogues: Synthesis and anti-HIV-1 activity. J Med Chem 1994, 37: 4185-94.
69. Taylor, D.L. et al. Anti-human immunodeficiency virus activity, bioavailability and drug resistance profile of the novel proteinase inhibitor MDL 74,695. Antivir Chem Chemother 1997, 8: 205.
70. Bacheler, L.T., Anton, E., Baker, D., Cordova, B., Fiske, W., Garber, S., Logue, K., Rizzo, C., Tritch, R., Erickson-Viitanen, S. Impact of mutation, plasma protein binding and pharmacokinetics on clinical efficacy of the HIV-1 non nucleoside reverse transcriptase inhibitor, DMP 266. 37th Intersci Conf Antimicrob Agents Chemother (Sept 29-Oct 1, Toronto) 1997, Abst 1-115.
71. Hanasaki, Y., Watanabe, H., Katsuura, K. et al. Thiadiazole derivatives: Highly potent and specific HIV-1 reverse transcriptase inhibitors. J Med Chem 1995, 38: 2038-40.
72. Bell, F.W., Cantrell, A.S., Hogberg, M. Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relationship studies of PETT analogs. J Med Chem 1995, 38: 4929-36.
73. Creagh, T., Xu, Z.-Q., Ray, L., Giltner, J., Nayer, T., Ruckle, J. Preliminary clinical safety profile of (+)-calanolide A - A new novel NNRTI. 5th Conf Retroviruses Opportunistic Infect (Feb 1-5, Chicago) 1998, Abst 652.
74. Newman, R.A., Madden, T. Preclinical pharmacology of novel rain forest-derived anti-HIV compounds: Costatolide (NSC-661122), 7, 8-dihydrocostatolide (NSC-661123) and calanolide A (NSC-664737). Proc Amer Assoc Cancer Res 1995, 36: Abst 1858.
75. Yang, S.S., Fliakas-Boltz, V., Bader, J.P., Buckheit, R.W. Jr. Characteristics of a group of nonnucleoside reverse transcriptase inhibitors with structural diversity and potent anti-human immunodeficiency virus activity. Leukemia 1995, 9(Suppl. 1): S75-85.
76. Flavin, M.T., Buckheit, R.W. Jr., Roca-Acin, J., Xu, Z.-Q. In vitro anti-human immunodeficiency virus (HIV) activity of (+)-calanolide A. 4th Conf Retroviruses Opportunistic Infect (Jan 22-26, Washington DC) 1997, Abst.
77. Newman, R.A., Chen, W., Madden, T. Preclinical pharmacology and pharmacokinetics of the calanolides, a novel series of nonnucleoside anti-HIV compounds. Proc Amer Assoc Cancer Res 1996, 37: Abst 2787.
78. Buckheit, R.W. Jr., Fliakas-Boltz, V., Pallansch, L.A. Effect of specific amino acid changes on the anti-HIV activity of NNRTIs: Confirmation of NNRTI-resistant virus subgrouping and selection of compounds for combination therapy. Antivir Res 1995, 26(3): Abst 67.
79. Baker, D.C., Deshpande, P.D., Tagliaferri, F., Victory, S.F., Yan, S. Total synthesis of optically active calanolide A and its diastereomers. 209th ACS Natl Meet (April 2-6, Anaheim) 1995, Abst ORGN 041.
80. Baker, D.C., Adah, S.A., Bauerdort, K., Deshpande, P.P., Gaines, M., Goncharenko, M.P., Sun, K.-L, Tagliaferri, F., Victory, S.F., Yan, S. Calanolides A and B. Synthesis, activities, and structure-activity relationships among congeners. Antivir Res 1996, 30(1): Abst 76.
81. Currens, M.J., Mariner, J.M., McMahon, J.B., Boyd, M.R. Generation and characterization of resistance to calanolide A, a novel nonnucleoside RT inhibitor, by HIV-1. FASEB J 1996, 10(3): Abst 1055.
82. Calanolide A development status. MediChem Research, Inc. Company Communication Feb 19, 1999.
83. Kashman, Y., Gustafson, K.R., Fuller, R.W., Cardellina, J.H. II, McMahon, J.B., Currens, M.J., Buckheit, R.W. Jr., Hughes, S.H., Cragg, G.M., Boyd, M.R. The calanolides, a novel HIV-inhibitory class of coumarin derivatives from the tropical rain forest tree, Calophyllum lanigerum (erratum). J Med Chem 1993, 36: 1110.
84. Khilevich, A., Rizzo, J.D., Flavin, M.T. et al. A versatile approach for synthesis of 2,3-dimethyl chroman-4-ones, intermediate for calanolide anti-HIV agents, via aldol/Mitsunobu reactions. Synth Commun 1996, 26: 3757-71.
85. Rao, A.V.R., Gaitonde, A.S., Prakash, K.R.C., Rao, S.P. A concise synthesis of chiral 2-methyl chroman-4-ones: Stereoselective build-up of the chromanol moiety of anti-HIV agent, calanolide A. Tetrahedron Lett 1994, 35: 6347-50.
86. Palmer, C.J., Josephs, J.L. Synthesis of the Calophyllum coumarins. Tetrahedron Lett 1994, 35: 5363-6.
87. Shi, X., Attygalle, A.B., Liwo, A., Hao, M.-H., Meinwald, J. Absolute stereochemistry of soulattrolide and its analogues. J Org Chem 1998, 63: 1233-8.